Complex regional pain syndrome - False hopes and miscommunications.

Drug abuse Fibromyalgia Inflammatory pain Intravenous immunoglobulin Neuropathic pain Nociceptors Opioid Pain Reflex sympathetic dystrophy Sympatholytic drugs

Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 04 10 2018
accepted: 09 10 2018
pubmed: 15 1 2019
medline: 9 4 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

Complex regional pain syndrome (CRPS) has been considered to be an autoimmune disease and there have been clinical trials with intravenous immunoglobulin. Often the etiology of the so-called CRPS diagnosis cannot be discerned and there are no validated instruments that provide functional metrics. The term complex regional pain syndrome (CRPS), coined in 1994 to describe patients in whom the pain is out of proportion to the injury, was actually a diagnosis proposed during the American Civil War, but was originally known as causalgia. Physicians have long observed similar sensitivity and inflammatory symptoms following periods of immobilization and disuse, which generally resolve within a few months of remobilization. Following the original description, persistent disproportionate pain would come to be known under many other names until researchers theorized that it was related to dysfunction in the sympathetic nervous system, after which it acquired the moniker, Reflex Sympathetic Dystrophy ("RSD"). In the latter quarter of the twentieth century, after researchers failed to prove the connection between the pain and the sympathetic nervous system, a small cadre of physicians-without rigorous science-invented CRPS. This new descriptor, CRPS, has become not only a diagnosis without objective data but with proposed criteria involving ambiguous signs and symptoms with low specificity. It has led to patients being treated erroneously with sympatholytic drugs, with or without pharmaceutical or surgical blockade of the sympathetic nervous system, unwarranted use of ketamine infusions, inappropriate use of narcotics and nerve stimulation. Intravenous immunoglobulin infusions have not been effective in the treatment of chronic pain. The indiscriminate use of pain medications to treat subjective symptoms of unclear diagnoses can be a risk factor for opioid and analgesic misuse or abuse.

Identifiants

pubmed: 30639650
pii: S1568-9972(19)30008-4
doi: 10.1016/j.autrev.2018.10.003
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

270-278

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Christopher Chang (C)

Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, United States; Division of Pediatric Immunology and Allergy, Joe DiMaggio Children's Hospital, United States.

Patrick McDonnell (P)

Law Offices of McDonnell & Associates, King of Prussia, PA, United States.

M Eric Gershwin (ME)

Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, United States. Electronic address: megershwin@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH